You're Taking Standard Doses and Having Severe Reactions. Here's Why.

Your CYP2D6 enzyme is responsible for metabolizing roughly one-quarter of all drugs in clinical use. This includes antidepressants (SSRIs, tricyclics), opioids, beta-blockers, and a long list of psychiatric medications. It’s one of your liver’s most important drug-processing machines. When it works normally, you take a dose, your liver breaks it down, and you get therapeutic benefit without accumulation.

Here’s the problem: the CYP2D6 gene comes in multiple functional variants. Some people carry deletions, duplications, or non-functional copies. Poor metabolizers, roughly 7-10% of people with European ancestry, have either two non-functional copies or one functional copy. Poor metabolizers break down drugs at a fraction of the normal rate, causing medications to build up to toxic levels in the bloodstream even at standard doses. Ultra-rapid metabolizers, on the other hand, process drugs so fast that standard doses provide no therapeutic benefit at all.

If you’re a poor CYP2D6 metabolizer taking an antidepressant at standard dose, you might experience dizziness, tremors, severe nausea, sexual dysfunction, or emotional blunting far worse than the symptom you’re treating. With opioids, you may experience respiratory depression, confusion, or oversedation. With beta-blockers, your heart rate may drop dangerously low. Your doctor sees these side effects and assumes the drug isn’t right for you. In reality, the dose is simply too high for your body to handle.

Your CYP2C19 enzyme metabolizes medications for acid reflux (proton pump inhibitors like omeprazole), blood thinners (clopidogrel), and many antidepressants. It does two critical jobs: it breaks down some drugs into inactive forms, and it activates other drugs from inactive prodrugs into their active therapeutic forms. Clopidogrel is a prodrug that requires CYP2C19 to be converted into its active antiplatelet form.

The CYP2C19 gene has variants labeled *2, *3 (poor metabolizers), and *17 (ultra-rapid metabolizers). Poor metabolizers, roughly 2-15% of the population depending on ancestry, cannot efficiently convert clopidogrel into its active form. If you’re a poor CYP2C19 metabolizer taking clopidogrel after a stent or heart attack, the drug provides almost no antiplatelet protection, dramatically increasing your risk of clot and recurrent cardiac events. Meanwhile, some of your ancestry groups carry *17, which makes you an ultra-rapid metabolizer; you convert clopidogrel so fast that you have elevated bleeding risk.

With PPIs, poor metabolizers may actually experience better acid suppression (because the drug accumulates), but this can mask underlying conditions and create dependency. With antidepressants metabolized by CYP2C19, poor metabolizers accumulate the drug and experience side effects at standard doses. The problem is that clopidogrel’s efficacy is not measured by how you feel. You feel fine. You just have a clot forming silently, or you’re bleeding internally.

Your CYP2C9 enzyme metabolizes warfarin, the most-prescribed oral blood thinner in the world. It also breaks down NSAIDs (ibuprofen, naproxen), statins, and other medications. Warfarin is a narrow-margin drug, meaning the difference between a therapeutic dose and a bleeding dose is small. Your CYP2C9 variant directly determines how fast you clear warfarin from your body and thus how much dose you need.

Variants *2 and *3 are poor metabolizer variants, present in roughly 5-10% of people with European ancestry. Poor CYP2C9 metabolizers clear warfarin slowly, requiring significantly lower maintenance doses than the standard 5 mg to avoid accumulation and serious bleeding. If you’re a poor metabolizer and your doctor prescribes standard warfarin doses without knowing your genotype, you’re at high risk of supratherapeutic INR levels, internal bleeding, hemorrhagic stroke, or bleeding into joints. Conversely, ultra-rapid metabolizers (less common) need higher doses to achieve therapeutic anticoagulation.

With NSAIDs, poor metabolizers experience prolonged drug exposure and higher risk of GI bleeding or kidney injury. The warning label on ibuprofen says “use the lowest effective dose for the shortest duration.” For poor CYP2C9 metabolizers, even the lowest standard dose is too much. Your pharmacist doesn’t know this unless you’ve been genotyped. Your doctor doesn’t know this unless you tell them. The result is bleeding complications attributed to bad luck or the drug being dangerous, when in fact it’s a genotype mismatch.

Your VKORC1 gene encodes the vitamin K epoxide reductase enzyme, which is the actual target protein that warfarin blocks. VKORC1 variants determine your baseline sensitivity to warfarin independent of how fast you metabolize it. The most common variant, the -1639G>A SNP, comes in two forms (G or A allele).

The A allele, present in roughly 40% of people with European ancestry, creates a version of VKORC1 that is more sensitive to warfarin’s blocking effect. People with the A allele require lower warfarin doses because their vitamin K recycling is inherently more sensitive to inhibition. This is different from poor CYP2C9 metabolism (slower breakdown); this is baseline warfarin sensitivity hardwired into the target enzyme itself. You can have normal CYP2C9 function but still need lower warfarin doses because of your VKORC1 variant.

Combining CYP2C9 and VKORC1 genotyping is the gold standard for warfarin dosing. A person who is both a poor CYP2C9 metabolizer AND carries VKORC1 A alleles needs very low doses to avoid bleeding. Standard dosing algorithms ignore this and result in overdose. Without genetic guidance, you’re on a guessing game that could end in hemorrhage.

Your SLCO1B1 gene encodes a transporter protein that moves statins (cholesterol-lowering drugs) from your bloodstream into your liver cells, where they do their job. Common statins include simvastatin, pravastatin, and rosuvastatin. If SLCO1B1 works normally, statins are efficiently transported into liver cells and metabolized. If SLCO1B1 has variants, statins stay in your bloodstream longer, circulating through your muscles and other tissues.

The *5 variant (rs4149056 C allele), present in roughly 15% of the population, reduces the transporter’s function. People with SLCO1B1 variants have reduced statin uptake into the liver, causing statins to accumulate in the bloodstream and increase your risk of statin-induced muscle pain (myopathy) and breakdown (rhabdomyolysis). This is especially true with simvastatin, the most lipophilic statin. You take your statin for heart health, and within weeks you develop severe muscle pain, weakness, or brown urine (sign of muscle breakdown). Bloodwork may show elevated CK (creatine kinase). Your doctor either reduces the dose or switches you to a different statin, often pravastatin or rosuvastatin, which rely less on SLCO1B1 for uptake.

Without knowing your SLCO1B1 status, you might assume you’re statin-intolerant and avoid this drug class altogether, leaving your cardiovascular risk unmanaged. Or you might suffer through myopathy unnecessarily when a simple genotype-guided statin choice would eliminate the problem.

Your TPMT gene encodes thiopurine methyltransferase, an enzyme that inactivates thiopurine drugs used for autoimmune conditions (azathioprine, 6-mercaptopurine, 6-thioguanine). These drugs suppress your immune system and are used for rheumatoid arthritis, inflammatory bowel disease, lupus, and after organ transplant. TPMT inactivates these drugs, preventing toxic buildup. If TPMT function is low or absent, thiopurine metabolites accumulate to dangerous levels.

There are three TPMT phenotypes: normal metabolizers (roughly 89% of the population), intermediate metabolizers (10-11%), and poor metabolizers (0.3%). Poor TPMT metabolizers cannot inactivate thiopurine drugs, causing toxic accumulation and severe, potentially fatal bone marrow suppression. Within days to weeks of starting thiopurine at standard dose, a poor metabolizer may develop severe anemia, neutropenia (dangerously low white blood cell count), or thrombocytopenia (low platelets). This looks like the drug is toxic or you’re having a rare adverse reaction. In reality, your body simply cannot metabolize the drug.

Testing for TPMT is standard of care before starting thiopurines. If you’re a poor metabolizer, you either need a 90% dose reduction, a different drug class, or both. Intermediate metabolizers need dose reduction. The consequences of not testing are potentially life-threatening bone marrow suppression requiring hospitalization. This is one of the clearest examples of a gene-drug interaction where testing directly prevents serious harm.